statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Investors eyeing a purchase of Stoke Therapeutics Inc (STOK) stock, but cautious about paying the going market price of 12.82/share, might benefit from considering selling puts among the...

Commit To Buy Stoke Therapeutics At $10, Earn 26.8% Annualized Using Options

Stoke Therapeutics (NASDAQ:STOK - Get Free Report)s stock had its "overweight" rating reiterated by stock analysts at Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga...

Stoke Therapeutics (NASDAQ:STOK) Rating Reiterated by Cantor Fitzgerald

Latest Ratings for STOK
 DateFirmActionFromTo Jan 2022JefferiesInitiates Coverage OnBuy Dec 2021B of A SecuritiesInitiates Coverage OnBuy Nov 2021JP MorganUpgradesNeutralOverweight
 View More...

Assessing Stoke Therapeutics: Insights From 6 Financial Analysts

Leerink Partners analyst Rudy Li has maintained their bullish stance on STOK stock, giving a Buy rating on March 26. Rudy Li has given his Buy rati...

Strong Buy Rating for Stoke Therapeutics' STK-001 Backed by Positive KOL Feedback and Revolutionary Potential in Dravet Syndrome Treatment

Stoke Therapeutics (NASDAQ:STOK) stock soared by 73% following the report of updated data from a Phase 1/2 study of its STK-001, a drug for treatin...

Stoke Stock (NASDAQ:STOK) Soars 73% on Drug Update; Is There More Upside Left?

Stoke Therapeutics (NASDAQ:STOK - Free Report) had its price objective lifted by Needham  Company LLC from $14.00 to $22.00 in a research note published on Tuesday morning, Benzinga reports...

Needham & Company LLC Boosts Stoke Therapeutics (NASDAQ:STOK) Price Target to $22.00

HC Wainwright reaffirmed their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK - Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $35.00 price...

Stoke Therapeutics (NASDAQ:STOK) Earns "Buy" Rating from HC Wainwright

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Volume	704,158.00
52-Wk High	$16.40
52-Wk Low	$3.35

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.61	--	--	N/A
Q4'23	-$0.61	-$0.60	1.41%	BEAT
Q3'23	-$0.63	-$0.55	13.04%	BEAT
Q2'23	-$0.63	-$0.69	-8.71%	MISSED
Q1'23	-$0.70	-$0.53	24.38%	BEAT

STOK Stoke Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals